We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cannabidiol in inflammatory bowel diseases: a brief overview.
- Authors
Esposito, Giuseppe; Filippis, Daniele De; Cirillo, Carla; Iuvone, Teresa; Capoccia, Elena; Scuderi, Caterina; Steardo, Antonio; Cuomo, Rosario; Steardo, Luca
- Abstract
This minireview highlights the importance of cannabidiol (CBD) as a promising drug for the therapy of inflammatory bowel diseases (IBD). Actual pharmacological treatments for IBD should be enlarged toward the search for low-toxicityand low-cost drugs that may be given alone or in combination with the conventional anti-IBD drugs to increase their efficacy in the therapy of relapsing forms of colitis. In the past, Cannabis preparations have been considered new promising pharmacological tools in view of their anti-inflammatory role in IBD as well as other gut disturbances. However, their use in the clinical therapy has been strongly limited by their psychotropic effects. CBD is a very promising compound since it shares the typical cannabinoid beneficial effects on gut lacking any psychotropic effects. For years, its activity has been enigmatic for gastroenterologists and pharmacologists, but now it is evident that this compound may interact at extra-cannabinoid system receptor sites, such as peroxisome proliferator-activated receptor-gamma. This strategic interaction makes CBD as a potential candidate for the development of a new class of anti-IBD drugs.
- Publication
Phytotherapy research : PTR, 2013, Vol 27, Issue 5, p633
- ISSN
1099-1573
- Publication type
Journal Article
- DOI
10.1002/ptr.4781